dantrolene has been researched along with Disseminated Intravascular Coagulation in 7 studies
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.
Disseminated Intravascular Coagulation: A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "After 9 years of treatment for Parkinson's disease, a 68-year-old woman developed the complications of neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) while she was still receiving levodopa, bromocriptine and amantadine hydrochloride." | 8.78 | Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease. ( Ogawa, N; Yamawaki, Y, 1992) |
| "A 29-year-old man with C6 tetraplegia (ASIA A) using an implanted baclofen pump and intrathecal catheter infusion system for spasticity control developed severe spasticity, hyperthermia, hypotension, rhabdomyolysis, and disseminated intravascular coagulation after catheter disconnection." | 7.70 | Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure. ( Christopherson, MW; Reeves, RK; Stolp-Smith, KA, 1998) |
| "Dantrolene was effective on the elevated COK level and FUT-175 was effective on the DIC, and symptoms of NMS and DIC were completely improved after a period of 14 days." | 6.38 | [Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease]. ( Ogawa, N; Yamawaki, Y, 1991) |
| "After 9 years of treatment for Parkinson's disease, a 68-year-old woman developed the complications of neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) while she was still receiving levodopa, bromocriptine and amantadine hydrochloride." | 4.78 | Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease. ( Ogawa, N; Yamawaki, Y, 1992) |
| " Following initial improvement, she developed delayed rhabdomyolysis then haloperidol-induced neuroleptic malignant syndrome, which was treated with a total of 50 mg." | 3.78 | Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene. ( Hawryluck, LA; Kraeva, N; Riazi, S; Russell, T; Steel, AC, 2012) |
| "A 29-year-old man with C6 tetraplegia (ASIA A) using an implanted baclofen pump and intrathecal catheter infusion system for spasticity control developed severe spasticity, hyperthermia, hypotension, rhabdomyolysis, and disseminated intravascular coagulation after catheter disconnection." | 3.70 | Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure. ( Christopherson, MW; Reeves, RK; Stolp-Smith, KA, 1998) |
| "Dantrolene was effective on the elevated COK level and FUT-175 was effective on the DIC, and symptoms of NMS and DIC were completely improved after a period of 14 days." | 2.38 | [Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease]. ( Ogawa, N; Yamawaki, Y, 1991) |
| "Malignant hyperthermia is defined in the International Classification of Diseases as a progressive life-threatening hyperthermic reaction occurring during general anaesthesia." | 1.62 | Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists. ( Dalay, S; Girard, T; Hopkins, PM; Jenkins, B; McGrady, E; Patteril, M; Thacker, A, 2021) |
| "The status epilepticus was also attenuated by the use of thiamylal sodium." | 1.30 | [A successfully treated parkinsonian patient with neuroleptic malignant syndrome complicated by status epilepticus and disseminated intravascular coagulation]. ( Miyoshi, T; Motomura, S; Osoegawa, M; Tamura, K; Yamanaka, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Hopkins, PM | 1 |
| Girard, T | 1 |
| Dalay, S | 1 |
| Jenkins, B | 1 |
| Thacker, A | 1 |
| Patteril, M | 1 |
| McGrady, E | 1 |
| Russell, T | 1 |
| Riazi, S | 1 |
| Kraeva, N | 1 |
| Steel, AC | 1 |
| Hawryluck, LA | 1 |
| Lappa, A | 1 |
| Podestà , M | 1 |
| Capelli, O | 1 |
| Castagna, A | 1 |
| Di Placido, G | 1 |
| Alampi, D | 1 |
| Semeraro, F | 1 |
| Reeves, RK | 1 |
| Stolp-Smith, KA | 1 |
| Christopherson, MW | 1 |
| Osoegawa, M | 1 |
| Motomura, S | 1 |
| Yamanaka, H | 1 |
| Tamura, K | 1 |
| Miyoshi, T | 1 |
| Yamawaki, Y | 2 |
| Ogawa, N | 2 |
2 reviews available for dantrolene and Disseminated Intravascular Coagulation
| Article | Year |
|---|---|
Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease.
Topics: Aged; Antithrombins; Benzamidines; Dantrolene; Disseminated Intravascular Coagulation; Female; Guani | 1992 |
[Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease].
Topics: Aged; Benzamidines; Dantrolene; Disseminated Intravascular Coagulation; Female; Guanidines; Humans; | 1991 |
5 other studies available for dantrolene and Disseminated Intravascular Coagulation
| Article | Year |
|---|---|
Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists.
Topics: Acidosis; Body Temperature; Calcium; Carbon Dioxide; Compartment Syndromes; Dantrolene; Disseminated | 2021 |
Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene.
Topics: Anesthetics, Inhalation; Antipsychotic Agents; Body Temperature; Caffeine; Central Nervous System St | 2012 |
Successful treatment of a complicated case of neuroleptic malignant syndrome.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Dantrolene; Disseminated Intravascular Coagulatio | 2002 |
Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure.
Topics: Adult; Baclofen; Catheters, Indwelling; Dantrolene; Disseminated Intravascular Coagulation; Equipmen | 1998 |
[A successfully treated parkinsonian patient with neuroleptic malignant syndrome complicated by status epilepticus and disseminated intravascular coagulation].
Topics: Anticoagulants; Antiparkinson Agents; Bromocriptine; Dantrolene; Disseminated Intravascular Coagulat | 1999 |